Jefferies Cuts Inmode to Hold, Cites Macro Pressures
InMode Price Target Cut to $19.00/Share From $21.00 by Jefferies
InMode Analyst Ratings
InMode's Business Outlook: Maintaining a Hold Rating Amid Market Challenges and Lowered Forecasts
Barclays Lowers Price Target on InMode to $29 From $33, Maintains Overweight Rating
InMode Analyst Ratings
Canaccord Genuity Maintains Hold on InMode, Lowers Price Target to $16
InMode Analyst Ratings
InMode Analyst Ratings
Barclays Adjusts Price Target on InMode to $33 From $34, Maintains Overweight Rating
InMode Analyst Ratings
InMode Analyst Ratings
InMode Analyst Ratings
Analysts Offer Insights on Healthcare Companies: MaxCyte (GB:MXCT), Kura Oncology (KURA) and InMode (INMD)
InMode Analyst Ratings
Barclays Maintains Overweight on InMode, Lowers Price Target to $33
InMode Analyst Ratings
Analysts Offer Insights on Healthcare Companies: InMode (INMD), Ocular Therapeutix (OCUL) and Adverum Biotechnologies (ADVM)
Canaccord Genuity Reiterates Hold on InMode, Maintains $22 Price Target
InMode Analyst Ratings